A Vermont overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
29.0% of Vermont adults have obesity, per CDC BRFSS 2024 data 1. The trend is the story: 26.8% in 2022, 28.8% in 2023, 29.0% in 2024 1.
Vermont's Medicaid program is unusually specific about which GLP-1 goes with which diagnosis, and none of those diagnoses is obesity on its own.
No. Vermont Medicaid (Green Mountain Care) fee-for-service does not cover any GLP-1 or GIP medication when obesity or weight loss is the qualifying diagnosis.
Under the state's own Preferred Drug List, effective August 1, 2026: older GLP-1s (Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza) require a type 2 diabetes diagnosis; Wegovy is covered only for MACE-risk reduction (BMI over 27 plus a prior stroke, heart attack, or peripheral artery disease) or MASH, never for weight loss alone; Zepbound is covered only for obstructive sleep apnea (AHI over 15, BMI over 30, on CPAP) 3. There is no Medicaid pathway to these drugs for obesity or weight management alone 3.
Vermont is not an outlier here — most state Medicaid programs decline to cover these drugs for obesity 4 — but the drug-by-drug carve-outs above are Vermont's own document, not a national template.
Astra's price in Vermont is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose.
Vermont sharpens why that matters. Median household income is $82,730 and the uninsured rate is roughly 4.2% (ACS 2024 1-year estimates) 5, among the lowest in the country. Vermonters are, by and large, insured — and still hit the same Medicaid wall described above when the diagnosis is obesity.
TODO — not yet verified. Vermont-specific telehealth prescribing rules (real-time audio-video requirements, out-of-state prescriber licensure and reciprocity, any DEA-adjacent controlled-substance telehealth limits) were not verified in this research pass, and nothing here should be treated as final.
The regulator to confirm with is the Vermont Office of Professional Regulation / Board of Medical Practice: sos.vermont.gov/opr/.
Astra serves patients in all 50 states, Vermont included, across a population of 648,493 (Census Vintage 2024 estimate) 2. Visits and refills are handled online, with medication from a state-licensed US compounding pharmacy.
Burlington, Vermont's largest city, has its own page below.
Astra treats patients in Vermont through state-licensed physicians.
Burlington: local coverage and cost detail.
No. Vermont Medicaid (Green Mountain Care) fee-for-service does not cover GLP-1 or GIP medications when obesity or weight loss is the reason for treatment. Coverage exists only for separately-qualifying diagnoses: Type 2 diabetes for older GLP-1s, MACE-risk reduction or MASH for Wegovy, and obstructive sleep apnea for Zepbound (Vermont DVHA Preferred Drug List, effective Aug 1, 2026; KFF, Jan 2026 issue brief).
No, and that's deliberate. Astra prices semaglutide at $68/mo and tirzepatide at $118/mo on 12-month plans ($816 / $1,416 billed annually) — the same price in Vermont as in every other state. What changes from place to place is what local clinics charge out of pocket, not Astra's price.
Because Vermont Medicaid doesn't cover GLP-1s for obesity, Vermonters who don't qualify under one of the narrower covered diagnoses are generally paying cash-pay clinic rates or brand list price. See the local pricing section on Astra's Burlington page for named, dated examples from clinics that publish their prices.
Yes. Astra is licensed to treat patients in all 50 states, which includes every city and rural area in Vermont. Care is delivered entirely by telehealth, so location within the state doesn't change access or price.
No. Astra's intake, consultation, prescribing, and follow-up all happen through telehealth, so no in-person visit is required to get started.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.